CARSKIN: Pembrolizumab as first line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC).

E. Maubec,Sabine Helfen,Isabelle Scheer-Senyarich,Marouane Boubaya,Olivier Schischmanoff,Céline Alloux,L. Deschamps,Peter Petrow,Isabelle Lopez,Annick Tibi,Vincent Levy

CARSKIN: Pembrolizumab as first line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC).

2017

E. Maubec
Sabine Helfen
Isabelle Scheer-Senyarich
Marouane Boubaya
Olivier Schischmanoff
Céline Alloux
L. Deschamps
Peter Petrow
Isabelle Lopez
Annick Tibi
Vincent Levy

TPS9596Background: Treatment options are limited for patients (pts) with locally advanced or metastatic cSCCs. Cisplatin-based combinations have some efficacy but their toxicity often prohibits the...

Keywords:

Cutaneous squamous cell carcinoma
Oncology
Pembrolizumab
Pathology
Medicine
Internal medicine
Toxicity
in patient
first line therapy
locally advanced
Cisplatin
treatment options

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations